Table 4.
Hazard of discontinuing buprenorphine treatment by setting (n=4180)
| Hazard Ratio (95% CI) | |
|---|---|
| Settinga (vs. B-PSY) | |
| B-OBOT | 0.27 (0.24–0.31)b |
| B-OPH | 0.46 (0.39–0.54)b |
| B-PHA | 0.70 (0.61–0.81)b |
| Sex (vs. male) | |
| female | 1.06 (0.98–1.14) |
| Race (vs. non-white) | |
| white | 0.77 (0.69–0.85)b |
| Age (vs. 30+) | |
| <21 | 1.44 (1.14–1.82)b |
| 21–24 | 1.23 (1.09–1.38)b |
| 25–29 | 1.06 (0.98–1.15) |
| Urbanicity (vs. central metro) | |
| fringe metro | 1.02 (0.92–1.14) |
| small/med metro | 0.65 (0.58–0.74)b |
| micropolitan | 0.83 (0.73–0.95)b |
| rural | 0.78 (0.69–0.88)b |
| Eligibility Type (vs. other) | |
| pregnancy | 1.20 (1.03–1.41)b |
| Psych Comorbidity (vs. none) | |
| any | 1.13 (1.05–1.22)b |
| SUD Comorbidity (vs. none) | |
| any | 1.14 (1.05–1.24)b |
| Elixhauser | 1.06 (1.03–1.08)b |
a
B-PSY, buprenorphine treatment in psychosocial program; B-OBOT, buprenorphine treatment in office-based setting; B-OPH, buprenorphine treatment in outpatient hospital; B-PHA, buprenorphine without billed treatment setting
b
Statistically significant at conventional threshold (p<0.05).